Mesoblast Limited
(ASX:MSB) has welcomed results from the latest round of trials for chronic low back pain.
The regenerative medicine developer has reported positive 24-month results in its phase 2 trial and announced the initiation of its phase 3 program.
Mesoblast says its product candidate, MPC-06-ID, has shown the potential to provide durable improvement in pain and function for chronic low back pain due to degenerative disc disease.
The company hopes the Phase 3 program may potentially provide a therapeutic modality for this major unmet need.
Mesoblast reported a net loss of $80.95 million in the full 2014 financial year.
